SLC5A2 and type 2 diabetes mellitus: This discrepancy in treatment may have significant clinical consequences; SGLT2 inhibitors significantly reduce deaths from cardiovascular conditions, hospitalizations for heart failure, and progression of kidney disease among patients with Type 2 diabetes [12].